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studies are necessary to understand the
immunopathogenesis of PR; such studies
should help clinicians identify patients
who are at higher risk for paradoxical de-
terioration during TB treatment and bet-
ter control its clinical manifestations.
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Glucose Homeostasis
Abnormalities and
Gatifloxacin
Sir—We read with interest the recent pub-
lication by Frothingham [1] reviewing
spontaneous adverse event reports (AERs)
on gatifloxacin-associated hypoglycemia
or hyperglycemia received by the US Food
and Drug Administration. Frothingham’s
review indicated a clear signal of a higher
rate of reports of glucose homeostasis ab-
normality for gatifloxacin, compared with
ciprofloxacin, levofloxacin and moxiflox-
acin. Our own review [2] of the sponta-
neous AERs received by the Canadian Ad-
verse Drug Reaction Monitoring Program
reported findings that paralleled those
made by Frothingham. The Canadian Ad-
verse Drug Reaction Monitoring Program
tracks reports of hypoglycemia or hyper-
glycemia in a category called “Metabolic
and Nutritional Disorders.” We found that
93% of all spontaneous AERs in this cat-
egory for gatifloxacin involved either hy-
poglycemia or hyperglycemia. Conversely,
only 11% of reports for levofloxacin and
10% of reports for moxifloxacin in this
category involved either hypoglycemia or
hyperglycemia. Analysis of our data in-
dicated that there were significantly more
reports of hypoglycemia ( ) asso-P ! .008
ciated with gatifloxacin treatment than
with either levofloxacin or moxifloxacin
treatment. Similarly, the total number of
reports involving glucose homeostasis ab-
normalities (either hypoglycemia or hy-
perglycemia) were significantly higher for
gatifloxacin ( ). The signal wasP ! .0001
even more striking when we observed that
the number of retail prescriptions for ga-
tifloxacin in Canada during the period of
analysis was approximately one-tenth of
the number of levofloxacin retail prescrip-
tions and one-third of the number of
moxifloxacin retail prescriptions [3]. Al-
though we acknowledge the limitations of
spontaneous AERs, we would like to high-
light the importance of AER surveillance
in detecting adverse events that occur
rarely (i.e., in !1% of patients) [1].
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